Published in Clin Transl Allergy on January 24, 2015
A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia). Patient Prefer Adherence (2017) 0.75
Critical appraisal of Timothy grass pollen extract GRAZAX(®) in the management of allergic rhinitis. Drug Des Devel Ther (2015) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (2007) 2.77
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy (2007) 2.10
Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol (2007) 1.84
Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol (2011) 1.78
Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol (2010) 1.63
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy (2001) 1.56
Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol (2007) 1.52
Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol (2009) 1.44
Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy (1994) 1.43
Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy (2012) 1.41
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 1.33
BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy (2008) 1.29
GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy (2010) 1.28
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol (1997) 1.27
Systematic reviews of sublingual immunotherapy (SLIT). Allergy (2011) 1.25
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol (2009) 1.23
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy (2013) 1.22
BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy (2007) 1.20
Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy (2006) 1.15
Characterisation of atopic and non-atopic wheeze in 10 year old children. Thorax (2004) 1.09
Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy (1993) 1.08
Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics (2000) 1.04
Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol (2008) 1.00
Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol (2012) 1.00
Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy (2004) 0.99
No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc (2003) 0.97
Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol (2007) 0.97
Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy (2001) 0.96
Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy (2013) 0.95
Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease. J Allergy Clin Immunol (2003) 0.95
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol (2010) 0.94
Quality of life in children and adolescents with allergic rhinitis. Braz J Otorhinolaryngol (2009) 0.93
Allergic rhinitis in children with asthma: a questionnaire-based study. Clin Exp Allergy (2008) 0.93
Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol (2006) 0.90
Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol (2005) 0.90
Characterisation of asthma that develops during adolescence; findings from the Isle of Wight Birth Cohort. Respir Med (2011) 0.89
Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol (2001) 0.85
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol (2004) 0.85
Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy (2010) 0.85
Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol (2008) 0.83
Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta-analysis. J Allergy Clin Immunol Pract (2012) 0.83
Specific immunotherapy in children. Clin Exp Allergy (2011) 0.79
A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety. Clin Exp Allergy (2011) 0.78
The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy (2001) 0.78
Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis. Int Arch Allergy Immunol (2008) 0.78
Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract (2014) 0.77
Do the leukotriene receptor antagonists work in children with grass pollen-induced allergic rhinitis? Pediatr Allergy Immunol (2006) 0.76